


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+6.22%
-5.73%
-3.09%
-26.83%
GILD
Gilead Sciences
$146.51
Strengths

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Risk Analysis

Earnings are forecast to decrease
GILD Price Performance
$143.28 (+2.25%)
$122.62 (+19.48%)
$116.62 (+25.63%)
$110.23 (+32.91%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to decrease
Trading below its fair value
GILD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
GILD Street Sentiment is bullish but have mixed views on the near-term outlook
GILD has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Jan 12, 2026
Upgrade
the stock
Citi
Dec 13, 2025
Reiterate
Overweight
Morgan Stanley
Dec 10, 2025
Reiterate
Buy
Cantor Fitzgerald
Nov 14, 2025
Initiate
Outperform
Scotiabank
Nov 14, 2025
Reiterate
Buy
Needham
ACLX
Arcellx Inc.
114.09
+0.04%
CGEN
Compugen
2.10
-4.89%
AGEN
Agenus
3.18
-4.79%
What is GILD current stock price?
What are GILD stock strengths?
What is GILD Risk Level?
What is GILD market cap and volume?
What is GILD current Stock IQ?
Should I buy GILD stock right now?
Is GILD a Strong Buy right now?
What does a 'Strong Buy' rating mean for GILD?
What does a 'Strong Sell' rating mean for GILD?
What factors influence GILD's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
GILD
Gilead Sciences
Current Price
$146.51
Runners Also Watch
ACLX
Arcellx Inc.
114.09
+0.04%
CGEN
Compugen
2.10
-4.89%
AGEN
Agenus
3.18
-4.79%

GILD Price Performance
$143.28 (+2.25%)
$122.62 (+19.48%)
$116.62 (+25.63%)
$110.23 (+32.91%)
GILD Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Investors confidence is positive
Future
Future
Earnings are forecast to decrease
Trading below its fair value
GILD Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
GILD Street Sentiment is bullish but have mixed views on the near-term outlook
GILD has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
GILD Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Risk Analysis

Earnings are forecast to decrease
GILD Latest Analysis
P/E Ratio Insights for Gilead Sciences. In the current market session Gilead Sciences Inc. (NASDAQ:GILD) stock price is at $147.00 after a 1.31% decrease. However over the past month the company'.s stock increased by 4.93% and in the past year by 28.42%. Shareholders might be interested in knowing whether the stock is overvalued even if the company is not performing up to par in the current session. Evaluating Gilead Sciences P/E in Comparison to Its PeersThe P/E ratio is used by long-term s
Fri Feb 27, 2026
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug. On Monday GILD) announced it is acquiring ) to enhance its .Gilead currently owns approximately 11.5% of Arcellx’.s outstanding common stock.Gilead Sciences on Monday agreed to acquire Arcellx for $115 per share in cash along with a contingent value right of $5 per share totaling an implied equity value of $7.8 billion.The acquisition aims to provide Gilead with full control over anitocabtagene autoleucel (anito-cel) a promising for
Mon Feb 23, 2026
Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus. Gilead Sciences Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20 Barclays began coverage of Gilead Sciences Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has [….]
Mon Feb 23, 2026
Time To Take Profits On Gilead Sciences (Rating Downgrade).
Fri Feb 20, 2026
Is Most-Watched Stock Gilead Sciences Inc. (GILD) Worth Betting on Now?. Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So it is worth exploring what lies ahead for the stock.
Thu Feb 19, 2026
Gilead in up to $1.5B deal with Chinas Genhouse Bio for tumor candidate.
Tue Feb 17, 2026
Can Gileads HIV Portfolio Sustain Its Growth Trend in 2026?. Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.
Fri Feb 13, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GILD Stock trends
GILD Stock performance
GILD Stock analysis
GILD investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.